Comparative Pharmacology
Head-to-head clinical analysis: EOHILIA versus FLAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EOHILIA versus FLAC.
EOHILIA vs FLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
FLAC (Fluorouracil) is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. It is converted to active metabolites (FdUMP, FUTP) that disrupt RNA function and DNA replication.
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
Adults: 40 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
2-4 hours; prolonged in renal impairment (up to 12 hours)
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%
Category C
Category C
Corticosteroid
Corticosteroid